Login to Your Account



Regeneron's VEGF Trap Misses in NSCLC; Focus Stays on AMD

By Jennifer Boggs


Monday, March 14, 2011
Anti-angiogenic drug aflibercept (VEGF-Trap) failed to improve overall survival in a Phase III trial in non-small-cell lung cancer, news that came as no surprise to analysts who have criticized Regeneron Pharmaceuticals Inc.'s and partner Paris-based Sanofi-Aventis SA's aggressive move into late-stage trials.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription